DUBLIN, Oct. 11, 2018 /PRNewswire/ -- Allergan
plc (NYSE: AGN), a leading global
pharmaceutical company, announced today that it will present 13
abstracts at the annual American Society for Dermatologic Surgery
(ASDS) meeting in Phoenix, AZ from
October 11-14.
The meeting will be held at the JW Marriott Desert Ridge Resort
& Spa and the scheduled times (noted in local Mountain Time) of
the presentations, titles and authors are as follows:
Oral presentations include:
- Safety and Efficacy of OnabotulinumtoxinA for Treatment of
Masseter Muscle Hypertrophy: Results from a Phase 2B Study.
-
- Authors: Carruthers J, Liew S, et al.
- Thursday, October
11th, 4:22
p.m.
- Session OA145: Oral Abstract Presentations- Grand Sonoran
F
- Understanding the African American Facial Aesthetic
Patient.
-
- Authors: Callendar V, Boyd C, et al.
- Thursday, October
11th, 5:27
p.m.
- Session OA145: Oral Abstract Presentations- Grand Sonoran
F
- ATX-101 Treatment Among Adults with Mild Submental Fat: Data
from CONTOUR.
-
- Authors: Weinkle S, Biesman B, et al.
- Friday, October 12th,
11:22 a.m.
- Session OA200: Oral Abstract Presentations- Grand Saguaro
North-South
- Preplatysmal Fat Volume is Reduced by Approximately 25%
Among ATX-101 Treatment Responders: Analysis of the REFINE
Data.
-
- Authors: Chesnut C, Joseph J, et al.
- Friday, October 12th
11:52 a.m.
- Session OA200: Oral Abstract Presentations- Grand Saguaro
North-South
The following posters will be on display from noon, Thursday, October 11th to 2 p.m.
Saturday, October
13th:
- Efficacy, Safety, and Patient-Reported Outcomes in Male
Subjects Treated With OnabotulinumtoxinA for Improvement of
Moderate to Severe Horizontal Forehead Lines.
-
- Authors: Keaney T, Cavallini M, et al.
- Efficacy and Patient-Reported Outcomes of OnabotulinumtoxinA
for Treatment of Moderate to Severe Horizontal Frontalis Lines in
Millennials.
-
- Authors: Palm M, Few J, et al.
- Development of Patient-Reported Outcome Measures for
Masseter Prominence.
-
- Authors: Fabi S, Narurkar V, et al.
- Efficacy, Safety, and Patient-Reported Outcomes Following
OnabotulinumtoxinA Treatment for Moderate to Severe Forehead Lines:
A Pooled Analysis of Two Phase 3 Pivotal Trials.
-
- Authors: De Boulle K, Fagien S, et al.
- OnabotulinumtoxinA for the Treatment of Forehead and
Glabellar Lines: Patient-Reported Satisfaction and Impact.
-
- Authors: Dayan S, Ogilvie P, et al.
- Understanding the Asian American Facial Aesthetic
Patient.
-
- Authors: Mariwalla K, Chiu A, et al.
- Understanding the Hispanic Facial Aesthetic
Patient.
-
- Authors: Bucay V, Montes JR, et al.
- Best Practice for the Use of ATX-101 for Submental
Contouring.
-
- Authors: Keaney T, Schlesinger T, et al.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global
pharmaceutical leader. Allergan is focused on developing,
manufacturing and commercializing branded pharmaceutical, device,
biologic, surgical and regenerative medicine products for patients
around the world.
Allergan markets a portfolio of leading brands and best-in-class
products for the central nervous system, eye care, medical
aesthetics and dermatology, gastroenterology, women's health,
urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of
research and development, which defines our approach to identifying
and developing game-changing ideas and innovation for better
patient care. With this approach, Allergan has built one of the
broadest development pipelines in the pharmaceutical industry.
Allergan's success is powered by our global colleagues'
commitment to being Bold for Life. Together, we build bridges,
power ideas, act fast and drive results for our customers and
patients around the world by always doing what is right.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives every day.
For more information, visit Allergan's website
at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective on existing trends and
information as of the date of this release. Actual results may
differ materially from Allergan's current expectations depending
upon a number of factors affecting Allergan's business. These
factors include, among others, the difficulty of predicting the
timing or outcome of FDA approvals or actions, if any; the impact
of competitive products and pricing; market acceptance of and
continued demand for Allergan's products; the impact of uncertainty
around timing of generic entry related to key products, including
RESTASIS®, on our financial results; uncertainty
associated with financial projections, projected cost reductions,
projected synergies, restructurings, increased costs, and adverse
tax consequences; difficulties or delays in manufacturing; and
other risks and uncertainties detailed in Allergan's periodic
public filings with the Securities and Exchange Commission,
including but not limited to Allergan's Annual Report on Form 10-K
for the year ended December 31, 2017
and Allergan's Quarterly Report on Form 10-Q for the period ended
March 31, 2018. Except as expressly
required by law, Allergan disclaims any intent or obligation to
update these forward-looking statements.
© 2018 Allergan. All rights reserved. All trademarks are the
property of their respective owners.
CONTACTS:
Allergan:
Investors:
Daphne Karydas
(862) 261-8006
Karina Calzadilla
(862) 261-7328
Media:
Amy Rose
(862) 289-3072
Ember Garrett
(714) 246-3525
View original content to download
multimedia:http://www.prnewswire.com/news-releases/allergan-to-present-data-from-13-abstracts-at-the-2018-american-society-for-dermatologic-surgery-meeting-in-phoenix-300729839.html
SOURCE Allergan plc